BGBIO Stock Overview
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
BerGenBio ASA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.19 |
52 Week High | kr4.95 |
52 Week Low | kr0.075 |
Beta | 1.39 |
1 Month Change | 1.04% |
3 Month Change | -30.22% |
1 Year Change | -96.06% |
3 Year Change | -99.37% |
5 Year Change | -99.20% |
Change since IPO | -99.22% |
Recent News & Updates
Recent updates
Here's Why BerGenBio (OB:BGBIO) Must Use Its Cash Wisely
Dec 07BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Aug 24BerGenBio (OB:BGBIO) Will Have To Spend Its Cash Wisely
Feb 06Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Sep 26Will BerGenBio (OB:BGBIO) Spend Its Cash Wisely?
Jun 11Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Feb 17We're Not Very Worried About BerGenBio's (OB:BGBIO) Cash Burn Rate
Sep 21It's Unlikely That The CEO Of BerGenBio ASA (OB:BGBIO) Will See A Huge Pay Rise This Year
Mar 13We're Interested To See How BerGenBio (OB:BGBIO) Uses Its Cash Hoard To Grow
Feb 11What Kind Of Investors Own Most Of BerGenBio ASA (OB:BGBIO)?
Dec 21Shareholder Returns
BGBIO | NO Biotechs | NO Market | |
---|---|---|---|
7D | -1.0% | 2.6% | 1.2% |
1Y | -96.1% | -68.7% | 4.1% |
Return vs Industry: BGBIO underperformed the Norwegian Biotechs industry which returned -68.7% over the past year.
Return vs Market: BGBIO underperformed the Norwegian Market which returned 5.4% over the past year.
Price Volatility
BGBIO volatility | |
---|---|
BGBIO Average Weekly Movement | 13.1% |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.3% |
10% most volatile stocks in NO Market | 10.3% |
10% least volatile stocks in NO Market | 2.8% |
Stable Share Price: BGBIO's share price has been volatile over the past 3 months.
Volatility Over Time: BGBIO's weekly volatility has decreased from 27% to 13% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 25 | Martin Olin | https://www.bergenbio.com |
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.
BerGenBio ASA Fundamentals Summary
BGBIO fundamental statistics | |
---|---|
Market cap | kr521.61m |
Earnings (TTM) | -kr190.40m |
Revenue (TTM) | kr354.00k |
1,473x
P/S Ratio-2.7x
P/E RatioIs BGBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BGBIO income statement (TTM) | |
---|---|
Revenue | kr354.00k |
Cost of Revenue | kr0 |
Gross Profit | kr354.00k |
Other Expenses | kr190.76m |
Earnings | -kr190.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | -0.071 |
Gross Margin | 100.00% |
Net Profit Margin | -53,785.59% |
Debt/Equity Ratio | 0% |
How did BGBIO perform over the long term?
See historical performance and comparison